Laparoscopic treatment of a Yolk Sac Tumor: case report and literature review

Maurizio Guida1, Sandro Pignata2, Anna Rita Palumbo1, Gianmarco Miele1, Maria Luisa Marra1, Federica Visconti1, Fulvio Zullo1

1Department of Gynaecology and Obstetrics, University of Salerno, Salerno, Italy.
2Department of urology and gynecology, National Cancer Institute, Naples, Italy

Corresponding Author: Maurizio Guida (e-mail: maguida@unisa.it)

SUMMARY

We report the case of a yolk sac tumor of the ovary in a 26 years old woman. The laparoscopic approach and the BEP chemotherapy were fundamental to have a minimally invasive treatment and to preserve fertility.

KEY WORD: ovary; yolk sac tumor; laparoscopic surgery; fertility.

INTRODUCTION

The ovarian germ cell tumors (OGCTs) [tab.1] represent 15-20% of all ovarian tumors [1] and originate from the primitive germ cell and then gradually differentiate to mimic the developmental tissues of embryonic origin (ectoderm, mesoderm, endoderm), and the extraembryonic tissues (yolk sac and trophoblast). Malignant Ovarian germ cell tumors (MOGCTs) constitute 3-5% of all ovarian malignancies [2,3]. OGCTs are subdivided into germinomatous e non-germinomatous tumors. The most common types of non-germinomatous tumors are yolk sac and immature teratoma. As regard as ovarian yolk sac tumors (YST) although rare, are the second most frequent histological subtype of MOGCTs, after ovarian dysgerminoma. They account for 20% of MOGCTs [4] and are frequent especially in childhood and in early adulthood, between 18-30 years old woman[5]. For this reason the treatment of yolk sac tumors is finalized to preserve the fertility and therefore it is imperative that these tumors are managed with accurate diagnosis, staging and treatment.

We report here the case of a 26 years old women with a YST treated with laparoscopic technique with success.

CASE-REPORT

A 26 years old female with body height of 1,68 m was admitted to our department with abdominal pain. She referred us a history of intermittent abdominal pain which had slowly been worsening over three month. In the last month there was loss of appetite. She reported amenorrhea for the past two cycles. She had no important past medical or surgical history. On palpation a vague mass was felt in the lower abdomen. The vaginal examination revealed a mass in the left fornix that was mobile and sore.

After the visit we executed an ultrasound examination with 3.5 MHz curvilinear probe that revealed a large mix echogenic mass measuring approximately 4cm in mayor diameter and 2,5 cm in smaller arising from pelvis that appears multilocular, cystic and solid in nature. At color doppler examination there was increased vascularity noted in the solid component of mass. No evidence of calcification. No fluid in the Douglas. The origin of the mass could not be ascertained, but was felt to be likely from the left ovary because a separate, normal left ovary could not be visualized. The right ovary appeared normally with the presence of a follicle of 1,5 cm.

Biochemical and laboratory investigations were made. Labs included a hemoglobin of 12,1 g/dl, a hematocrit of 37,9% and platelets of 275.000; creatinine was normal (0,76 mg/dl) and also BUN (32 mg/dl); liver function tests that included bilirubin (0,54 mg/dl), aspartate aminotrasferase (19 u/L), alanine aminotrasferase (17 u/L) were normal; Serum human gonadotropin hormone levels (4,2 mUI/ml) and CA-125 levels (293 UI/L) were within normal limits. A markedly elevated serum alpha-fetoprotein (AFP) level to 18.178 ng/ml oriented toward the diagnosis of an ovarian yolk sac tumor.

Subsequently, CT of the abdomen was performed. A 4,5 cm size complex mass lesion in the left ovary with solid component and cystic areas adjacent to it was present. Pelvic and paraaortic lymph nodes were in the range limits for the dimension and morphology. No calcified peritoneal implants were apparent, the others abdomen bowels appeared of normal structure.
Table 1: Subtypes and characteristics of ovarian germ cell tumours (data derived from Rice, 1999 and John Hopkins Pathology, 2001).

| Subtype               | Frequency of OGCT | Benign/malignant | Uni- or bilaterale | Tumour markers expressed | Metastasis route               |
|-----------------------|-------------------|------------------|--------------------|----------------------------|--------------------------------|
| Dysgerminoma          | 35-50 %           | malignant        | 10-15 % are bilateral | Serum lactic dehydrogenase and serum hGC | Lymphatic system               |
| Yolk sac tumor (YST)  | 20%               | malignant        | Usually unilateral  | AFP (commonly), alpha 1 antitrypsin (rarely) | Intraperitoneally and hematogenously |
| Embryonal carcinoma   | Rare              | malignant        |                    | AFP and hGC                | intraperitoneally               |
| Polyembrioma          | Rare              | malignant        |                    | AFP and hGC                |                                |
| Choriocarcinoma       | Very rare         | malignant        | Usually unilateral  | Hgc                        |                                |
| Teratoma              | Immature account for 20% of MOGCTs | Benign or malignant | 12-15 % are bilateral | Immature teratomas sometimes secrete AFP, serum LDH and Ca125 |                                |
| Mixed GCT             | 10-15%            | Dependent upon the cell types present |                    | Dependent upon the cell types present |                                |

After our evaluations we decided to plan a laparoscopic surgery. We provide the steps of surgery; after the creation of pneumoperitoneum with Verres needle, a central trocar was used for the optics, others three trocars were inserted as lateral operative accesses. The uterus and right adnexa appeared normal with no lesion; the left adnexa showed a large mass with cystic and necrotic aspects. There was no peritoneal carcinomatosis and no lesions on the liver or subdiaphragmatic areas. A peritoneal washing was made. After a total omentectomy, obturator and paraaortic lymph nodes dissection were also added to the left salpingo-oophorectomy; a biopsy of right ovary, of left parieto-colic sulcus and appendicectomy were made. Specimens were sent for histopathological examination [Tab2]. The left ovary mass showed tumor cells arranged in papillary groups with a glandular pattern and acinar structure. The lining of the papillary infolding was irregular. Also there was the presence of Schiller-Duvall body, typical patterns of YST. The postoperative course was regular and the alpha-fetoprotein levels decreased rapidly. It was planned a chemotherapy with the BEP regimen (Bleomycin, Etoposide, Cisplatin). A total of two cycles of chemotherapy were repeated every 3 weeks. Serum AFP level had fallen to normal range 4 weeks after the surgery.

**DISCUSSION**

Yolk sac tumor is also called endodermal sinus tumor (EST) because there is a link to its discovery. Histologically the malignant tissue resemble structure found in early embryonic development, and it is Shiller’s stressing of the unique glomeruloid structure that led Teliun to compare it with the yolk sac endodermal sinuses of Duval in the rat placenta[6].

High values of AFP orientate strongly to diagnosis of YST. Furthermore it is a sensible marker for tumor’s evolution; infact a rapid decrease of AFP levels in the serum after surgery is a sign of absence of residual tumor. Also the efficiency of chemotherapy its related with normalization of AFP [8]. It is almost always unilateral and large with a diameter that may vary from 5 to 50 cm (median 15 to 19 cm)[9]. The typical neoplasm manifest as a large complex pelvic mass that extends into the abdomen. This tumor is often characterized by extremely rapid growth and extensive intra-abdominal spreading with poor prognosis [10].

As regard clinical, abdominal pain is the principal symptom leading the discovery of the disease which may require the emergency surgery especially in cases of ovarian torsion [11]. Other symptoms are the presence of an abdominal or pelvic mass with abdominal enlargement, vaginal bleeding, fever, ascites or peritonitis secondary to torsion, infection or rupture of the ovarian tumor [3, 8]. In consequence of ascites it’s possible to have decrease breath sounds in the bilateral lung bases, diffuse tenderness to palpation of the abdomen and distant bowel sound [12].
Because of most of them are unilateral, it's possible tumors is complete surgical excision. The standard management of malignant ovarian germ cell also involved in advanced stages.[3, 13, 14]

Retroperitoneal lymph nodes and liver parenchyma were lower RI are detectable by color Doppler ultrasound, specific image both ultrasound that MRI and CT. If YST and areas of haemorrhage. However YST haven't a tumors can be cystic, with signs of hypervascularization. Preoperative radiological diagnosis is difficult. Yolk sac tumors can be cystic, with signs of hypervascularization and areas of haemorrhage. However YST haven’t a specific image both ultrasound that MRI and CT. If YST appear with a solid portion, multiple small arterioles with lower RI are detectable by color Doppler ultrasound, haemorrhagic spots can be demonstrated by T1 weighted MRI, hypervascularity can be shown on contrast-enhanced T1 weighted scans [7]. The malignant evolution of YST consist in locoregional extension involving uterus, pelvic peritoneum,rectum and bladder. Other authors described the involvement of the omentum, abdominal peritoneum and serosal surfaces of bowel in 30% of the cases. Retroperitoneal lymph nodes and liver parenchyma were also involved in advanced stages.[3, 13, 14] The standard management of malignant ovarian germ cell tumors is complete surgical excision. Because of most of them are unilateral, it’s possible executing a fertility sparing surgical treatment. The type of surgical procedure was not an important prognostic factor for patients with malignant germ cell tumors of the ovary at all clinical stages, and so the conservative surgery is possible if it’s followed by chemotherapy[15].

In the past after the laparoscopic diagnosis of an ovarian cancer, laparo-conversion was recommended to have an optimal staging and to avoid an uncertain tumor cell spread. Today, advancement in technologies offers a minimally invasive surgery that recognizes in the laparoscopic surgery a new approach for ovarian cancer. It gave us not only a same or even better surgical prognosis as compared the conventional laparotomy[16] but benefit from a less traumatic surgery and a potentially faster recovery[17].

The aim of surgery is removing the primary ovarian tumor without excessive morbidity. Thus cycles of chemotherapy should be administrate while monitoring the rate of decline of serum AFP. Specifically, before the introduction of effective combination chemotherapy, the prognosis for patients with malignant nondysgerminomatous cancers was poor; as regards patients with YST, they had a 3-year survival rate of 13% [18]. Currently, initial surgery followed by adjuvant chemotherapy including bleomycin, etoposide and cisplatin (BEP) is considered the standard for the treatment of YolkSacTumor [19]. Compared with other regimens, BEP appears to be the best active first-line option for primary, metastatic, or recurrent disease. As regards the chemotherapy-related toxicity, it was acceptable and severe collateral effects was infrequent, although myelosuppression can be observed in the majority of patients. The administration of G-CSF would help manage this toxicity. Infrequent severe pulmonary toxicity, ototoxicity, or nephrotoxicity are observed [20]. Administration of bleomycin as a slow infusion (over 24 h) may reduce the incidence of toxicity, but this has yet to be confirmed [19]. Administration of etoposide for three days instead of five, is an effort to decrease the incidence of neutropenia without sacrificing efficacy. Etoposide has been reported to be associated with the development of an acute leukemia with typical morphological and cytogenetic features [22]. Long-term toxicity was limited and consisted in hypertension, as already described in testicular cancer survivors [21-23]. Progressive or recurrent ovarian YST after treatment with BEP chemotherapy is associated with a poor prognosis. There are not approved schemes of chemotherapy in this cases, so it is possible adapt chemotherapy used for recidivist testicular cancer. Possible options of chemotherapy include combination of vinblastine, ifosfamide, cisplatinum, or paclitaxel, ifosfamide, cisplatinum, [24]. It should also be stressed that secondary cytoreductive surgery could play an important role when tumors are limited and resistant to chemotherapy. As regards the follow-up of chemotherapy, the determination of initially elevated markers (AFP) should be repeated before each cycle of therapy, soon after the end of the treatment and during the 2 years after the end of chemotherapy[20]. An annual pelvic ultrasound is necessary in the case of conservative treatment, to screen for a contralateral recurrence[25].

The BEP regimen, no ascites at presentation, stage I disease, less of 42 days to AFP normalization, fertility-sparing surgery and a serum AFP half-life less of 10 days are factors associated with a good prognosis.

Lumbaraoctic lymphadenectomy has been proposed to identify patients with a higher risk of relapse after surgery,

| Table2: pathologist report, Department of Pathology; University of Salerno, Salerno,Italy. |
|---------------------------------------------------------------|
| Macroscopic description | Microscopic description |
| Left ovary with mass (4.5 cm * 2 cm) + left fallopian tube (6 cm) | Residual ovarian parenchyma and cystic spaces lined by cells with clear cytoplasm and hyperchromatic nuclei arranged in papillary groups compatible with yolk sac tumor |
| Appendix (3 cm) | Absence of disease |
| Omentum with free areas of thickening (12 cm * 4 cm) + left parieto-colic sulcus (1.5 cm) | Absence of disease |
| Right ovary biopsy | Ovarian parenchyma with ovarian follicles and a corpus luteum |
| 6 paraaortic lymph nodes | Reactive hyperplasia |
| 9 obturator lymph nodes | Reactive hyperplasia |
| Peritoneal fluid | Inflammatory and mesothelial cells, absence of malignant cells |

Preoperative radiological diagnosis is difficult. Yolk sac tumors can be cystic, with signs of hypervascularization and areas of haemorrhage. However YST haven’t a specific image both ultrasound that MRI and CT. If YST appear with a solid portion, multiple small arterioles with lower RI are detectable by color Doppler ultrasound, haemorrhagic spots can be demonstrated by T1 weighted MRI, hypervascularity can be shown on contrast-enhanced T1 weighted scans [7]. The malignant evolution of YST consist in locoregional extension involving uterus, pelvic peritoneum,rectum and bladder. Other authors described the involvement of the omentum, abdominal peritoneum and serosal surfaces of bowel in 30% of the cases. Retroperitoneal lymph nodes and liver parenchyma were also involved in advanced stages.[3, 13, 14] The standard management of malignant ovarian germ cell tumors is complete surgical excision. Because of most of them are unilateral, it’s possible executing a fertility sparing surgical treatment. The type of surgical procedure was not an important prognostic factor for patients with malignant germ cell tumors of the ovary at all clinical stages, and so the conservative surgery is possible if it’s followed by chemotherapy[15].

In the past after the laparoscopic diagnosis of an ovarian cancer, laparo-conversion was recommended to have an optimal staging and to avoid an uncertain tumor cell spread. Today, advancement in technologies offers a minimally invasive surgery that recognizes in the laparoscopic surgery a new approach for ovarian cancer. It gave us not only a same or even better surgical prognosis as compared the conventional laparotomy[16] but benefit from a less traumatic surgery and a potentially faster recovery[17].

The aim of surgery is removing the primary ovarian tumor without excessive morbidity. Thus cycles of chemotherapy should be administrate while monitoring the rate of decline of serum AFP. Specifically, before the introduction of effective combination chemotherapy, the prognosis for patients with malignant nondysgerminomatous cancers was poor; as regards patients with YST, they had a 3-year survival rate of 13% [18]. Currently, initial surgery followed by adjuvant chemotherapy including bleomycin, etoposide and cisplatin (BEP) is considered the standard for the treatment of YolkSacTumor [19]. Compared with other regimens, BEP appears to be the best active first-line option for primary, metastatic, or recurrent disease. As regards the chemotherapy-related toxicity, it was acceptable and severe collateral effects was infrequent, although myelosuppression can be observed in the majority of patients. The administration of G-CSF would help manage this toxicity. Infrequent severe pulmonary toxicity, ototoxicity, or nephrotoxicity are observed [20]. Administration of bleomycin as a slow infusion (over 24 h) may reduce the incidence of toxicity, but this has yet to be confirmed [19]. Administration of etoposide for three days instead of five, is an effort to decrease the incidence of neutropenia without sacrificing efficacy. Etoposide has been reported to be associated with the development of an acute leukemia with typical morphological and cytogenetic features [22]. Long-term toxicity was limited and consisted in hypertension, as already described in testicular cancer survivors [21-23]. Progressive or recurrent ovarian YST after treatment with BEP chemotherapy is associated with a poor prognosis. There are not approved schemes of chemotherapy in this cases, so it is possible adapt chemotherapy used for recidivist testicular cancer. Possible options of chemotherapy include combination of vinblastine, ifosfamide, cisplatinum, or paclitaxel, ifosfamide, cisplatinum, [24]. It should also be stressed that secondary cytoreductive surgery could play an important role when tumors are limited and resistant to chemotherapy. As regards the follow-up of chemotherapy, the determination of initially elevated markers (AFP) should be repeated before each cycle of therapy, soon after the end of the treatment and during the 2 years after the end of chemotherapy[20]. An annual pelvic ultrasound is necessary in the case of conservative treatment, to screen for a contralateral recurrence[25].

The BEP regimen, no ascites at presentation, stage I disease, less of 42 days to AFP normalization, fertility-sparing surgery and a serum AFP half-life less of 10 days are factors associated with a good prognosis.

Lumbaraoctic lymphadenectomy has been proposed to identify patients with a higher risk of relapse after surgery,
in order to guide the choice of adjuvant chemotherapy [25].

In the study of de La Motte, Rouge and collaborators [4] lymphnode metastasis was found exclusively in 2 patients with stage IIIC peritoneal disease in whom chemotherapy is mandatory. No lymph node involvement was found in stage I disease.

Another important consideration is the impact of chemotherapy on gonadal and reproductive function. In the past the majority of patients with MOGCT receiving multidrug combination chemotherapy, showed a decreased number of primordial follicles and an increase in stromal fibrosis and in atrophied cortices [26]. Today for early stage disease the aim of chemotherapy is to be efficacy and at the same time to minimize toxicity and retain reproductive function [27, 28]. Different studies [29, 30] reported the resume of normal menstrual function and in some patients pregnancies after BEP chemotherapy. For example, Brewer et al reported on 26 patients treated with BEP for MOGCT, 71% of which resumed normal menstrual function, and six of whom conceived [29].

Therefore the risk of infertility following treatment of MOGCT is always a concern, even if the majority of patients, especially in the early stage, will maintain their ovarian function and fertility. Following this strategy, most patients will be cured and be able to give birth.

REFERENCES

[1] Robbins, Stanley L.; Kumar, Vinay; Cotran, Ramzi S. (2003). Robbins basic pathology(7th ed.). Philadelphia: Saunders. p. 664. ISBN 0-7216-9274-5.

[2] Kang. H, Kim TJ, Kim WY, Choi CH, Lee JW, Kim BG, Bae DS. Outcome and reproductive function after cumulative high-dose combination chemotherapy with bleomycin, etoposide and cisplatin (BEP) for patients with ovarian endodermal sinus tumor. Gynecol Oncol. 2008 Oct;111(1):106-10. Epub 2008 Jul 25.

[3] Dallenbach P, Bonnefoi H, Peltte MF, Vlastos G. Yolk sac tumours of the ovary: an update. Eur J Surg Oncol. 2008 Dec;32(10):1063-75. Epub 2006 Sep 22.

[4] de La Motte Rouge T, Pautier P, Rey A, Duvillard P, Kerbrat P, Troalen F, Morice C, Culfes C, Lhomme.

C. Prognostic factors in women treated for ovarian yolk sac tumour: a retrospective analysis of 84 cases. Eur J Cancer. 2011 Jan;47(2):175-82. Epub 2010 Sep 28.

[5] DiSaia PJ, Creasman WT: Germcell, stromal, and other ovarian tumors in: Gaertner R, Simpson D, editors. Clinical Gynecologic Oncology (7th ed). Philadelphia, Mosby Elsevier, 2007, pp 369-395.

[6] Tan KengKhoo, Donald P. C. Chan. Embryonal tumour of the ovary with the endodermal sinus pattern. Singapore medical journal –vol 7, N01, march 1966

[7] J Chin Med Assoc. 2007 Nov;70(11):514-8. Ultrasound and magnetic resonance images of endodermal sinus tumor. Hung JH, Shen SH, Hung J, Lai CR.

[8] Kehila M, Skhiri R, Boughizane S, Fekih M, Kebaili S, Rameh S, Agina M, Khairi H. Yolk sac tumor revealed by an ascite of great abundance. J Gynecol Obstet Biomat Reprod (Paris). 2009 Oct;38(6):516-20. Epub 2009 May 28.

[9] Lu KH, Gershenson DM. Update on the management of ovarian germ cell tumors. J Reprod Med. 2005 Jun;50(6):417-25. Review

[10] Telium G. Endodermal sinus tumors of the ovary and testis. Comparative morphogenesis of the so calledmesonephromaovarii (Shiller) and extraembryonic (yolk sac allantoic) structure of the rat’s placenta. Cancer 1959 nov-dec; 12; 1092-105

[11] Beurdeley M, Gauthier T, Piguet C, Fourcade L. Conservative treatment of big yolk sac tumour of the ovary in young girl. J Visc Surg. 2010 Aug;147(4):e265-7.

[12] J Pediatr Adolesc Gynecol. 2011 Feb;24(1):e1-3. Epub 2010 Sep 24. Malignant mixed ovarian germ cell tumor with embryonal component. Moniaga NC, Randall LM.

[13] Lal A, Mumtaz HA, Radhika S, Khandelwal N. Endodermal sinus tumor: a rare cause of calcified peritoneal implants. Cancer Imaging. 2009 Jun 15;9:29-31.

[14] Nowa A, Obata N, Kikkawa F, Kawai M, Nagasaka T, Goto S, Nishimori K, Nakashima N. Prognostic factors of patients with yolk sac tumors of the ovary. Am J Obstet Gynecol. 2001 May;184(6):1182-8.

[15] Nishio S., Ushijima K., Fukui A et al.: Fertility-preserving treatment for patients with malignant germ cell tumors of the ovary. J Obstet Gynaecol Res. 2006; 32: 416

[16] Tozzi R., Kohler C., Ferrara A., Schneider A. Laparoscopic treatment of early ovarian cancer: surgical and survival out-comes. Gynecol Oncol 2004; 93:199-203

[17] Lee CL, Kay N, Chen HL, Yen CF, Huang KG. The roles of laparoscopy in treating ovarian cancer. Taiwan J Obstet Gynecol. 2009 Mar; 48(1):9-14.

[18] Kurman RJ, Norris HJ. Endodermal sinus tumor of the ovary: a clinical and pathologic analysis of 71 cases. Cancer 1976;38:2404-19.
[19] Kang H, Kim TJ, Kim WY, Choi CH, Lee JW, Kim BG, Bae DS. Outcome and reproductive function after cumulative high-dose combination chemotherapy with bleomycin, etoposide and cisplatin (BEP) for patients with ovarian endodermal sinus tumor. Gynecol Oncol. 2008 Oct;111(1):106-10. Epub 2008 Jul 25.

[20] De La Motte Rouge T, Pautier P, Duvillard P, Rey A, Morice P, Haie-Meder C, Kerbrat P, Culline S, Troalen F, Lhomme C. Survival and reproductive function of 52 women treated with surgery and bleomycin, etoposide, cisplatin (BEP) chemotherapy for ovarian yolk sac tumor. Ann Oncol. 2008 Aug;19(8):1435-41. Epub 2008 Apr 11.

[21] Chisholm RA, Dixon AK, Williams MV, Oliver RT. Bleomycin lung: the effect of different chemotherapeutic regimens. Cancer Chemother Pharmacol 1992;30:158–60.

[22] Bajorin DF, Motzer RJ, Rodriguez E, Murphy B, Bosl GJ. Acute nonlymphocytic leukemia in germ cell tumor patients treated with etoposide-containing chemotherapy. J Natl Cancer Inst 1993;85:60–2.

[23] Sagstuen H, Aass N, Fossa SD et al. Blood pressure and body mass index in long-term survivors of testicular cancer. J Clin Oncol 2005; 23(22): 4980–4990.

[24] Kondagunta GV, Bacik J, Donadio A et al. Combination of paclitaxel, ifosfamide, and cisplatin is an effective second-line therapy for patients with relapsed testicular germ cell tumors. J Clin Oncol 2005; 23(27): 6549–6555.

[25] Tong X, You Q, Li L, Cai L, Wang C, Zheng J. Prognostic factors of patients with ovarian yolk sac tumors: a study in Chinese patients. Onkologie. 2008 Dec;31(12):679-84. Epub 2008 Nov 20.

[26] Schilskly RL, Lewis BJ, Sherins RJ, Young RC. Gonadal dysfunction in patients receiving chemotherapy for cancer. Ann Intern Med 1980 Jul;93(1):109-14.

[27] Gershenson DM, Management of ovarian germ cell tumors. J Clin Oncol . 2007 Jul 10;25(20):2938-43.